Using Next Generation Sequencing to Identify Mutations Associated with Repair of a CAS9-induced Double Strand Break Near the CD4 Promoter
March 31st, 2022
1.9K views
Presented here is sgRNA/CAS9 endonuclease and next-generation sequencing protocol that can be used to identify the mutations associated with double strand break repair near the CD4 promoter.
Overview
This article presents a protocol for identifying mutations that occur during the repair of double-strand breaks (DSBs) induced by CRISPR/Cas9 and single-guide RNA (sgRNA) at a specific genomic locus. The method is demonstrated using human keratinocyte cell lines and is adaptable to any transfectable cell type. The approach offers a cost-effective and robust alternative to whole genome sequencing for studying DSB repair mechanisms and associated mutagenesis.
Key Study Components
Area of Science
- DNA damage and repair
- Genome editing
- Molecular biology
Background
- Double-strand breaks are the most cytotoxic form of DNA damage and can arise from various sources, including replication stress and ionizing radiation.
- Unrepaired DSBs compromise genome integrity and can drive tumorigenesis.
- Traditional methods for studying DSB repair, such as whole genome sequencing after ionizing radiation, are computationally intensive and costly.
- CRISPR/Cas9 technology enables targeted induction of DSBs at any genomic locus, facilitating focused analysis of repair outcomes.
Purpose of Study
- To demonstrate a protocol for detecting mutations resulting from the repair of a Cas9-induced DSB upstream of the CD4 gene.
- To provide a cost-effective method for analyzing DSB repair at specific loci.
- To enable adaptation of the protocol for studying the effects of exogenous factors, such as repair inhibitors or viral proteins, on DSB repair fidelity.
Methods Used
- Culturing human keratinocyte cell lines (HFK LXSN and HFK 8E6).
- Transfection with plasmids expressing Cas9 and sgRNA targeting the CD4 locus.
- Assessment of transfection efficiency via immunoblot for Cas9 expression.
- Confirmation of DSB induction using immunofluorescence microscopy for phospho-H2AX (S139).
- Sequencing of DNA flanking the Cas9-induced DSB to identify and categorize mutations.
Main Results
- Both untransfected and transfected HFK cells showed similar Cas9 expression, indicating comparable transfection efficiency.
- Immunofluorescence confirmed induction of DSBs by Cas9/sgRNA.
- Genomic variations were categorized and compared between HFK LXSN and HFK 8E6 cells.
- HPV 8E6 expression increased genomic variations within 200 kb of the DSB, suggesting deregulation of DSB repair and increased genomic instability.
Conclusions
- The protocol enables efficient detection of mutations arising from DSB repair at targeted genomic loci.
- It is adaptable to various cell lines and genomic sites, provided the cells are transfectable.
- The method can be used to study the impact of different factors on DSB repair fidelity with limited computational requirements.
Frequently Asked Questions
What is the main advantage of using CRISPR/Cas9-induced DSBs for mutation analysis?
CRISPR/Cas9 allows precise induction of DSBs at any genomic locus, enabling focused and cost-effective analysis of repair-associated mutations without the need for whole genome sequencing.
How is transfection efficiency assessed in this protocol?
Transfection efficiency is measured by immunoblot analysis of Cas9 expression in both untransfected and transfected cells.
How is DSB induction confirmed?
DSB induction is confirmed using immunofluorescence microscopy to detect phosphorylated histone H2AX (S139), a marker of DNA double-strand breaks.
Can this protocol be adapted to other cell types or genomic loci?
Yes, the protocol can be adapted to any transfectable cell line and any genomic locus, provided the organism's genome has been sequenced and appropriate sgRNAs are designed.
What were the effects of HPV 8E6 expression on DSB repair?
HPV 8E6 expression increased the number of genomic variations near the Cas9-induced DSB, indicating that it deregulates DSB repair and promotes genomic instability.
What types of downstream analyses can this protocol support?
The protocol supports mutation frequency and type analysis, and can be used to assess the effects of repair inhibitors, viral proteins, mutations, or environmental exposures on DSB repair.
Why is this method more cost-effective than whole genome sequencing?
By targeting sequencing to regions flanking the induced DSB, the method reduces the amount of sequencing required and the associated computational burden, making it more affordable and accessible.
Executive Industry Relevance
Targeted identification of mutations arising from double-strand break (DSB) repair is critical for de-risking genome editing and understanding genomic instability mechanisms in drug discovery. This Cas9/sgRNA-directed next generation sequencing (NGS) workflow enables precise, locus-specific mutation profiling, supporting predictive confidence in DNA repair pathway interrogation. The approach streamlines early discovery and translational research by reducing computational burden and enabling scalable, cost-effective analysis of repair fidelity under diverse experimental conditions.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables mechanistic de-risking by directly linking DSB repair outcomes to specific genetic or environmental perturbations.
- Supports functional target validation by quantifying mutation types and frequencies at defined loci.
- Facilitates portfolio triage by revealing repair pathway vulnerabilities and mutagenic potential of candidate targets or factors.
Screening & Assay Development
- Prepares validated cell-based systems for high-confidence assessment of DNA repair modulators.
- Delivers reproducible, quantitative mutation readouts for assay standardization and downstream screening.
- Enables scalable, locus-specific mutation detection adaptable to multiple cell lines and genomic sites.
Translational & Preclinical Research
- Aligns with disease-relevant models by enabling mutation analysis in the context of viral proteins or repair inhibitors.
- Supports continuity from discovery to preclinical validation by allowing comparative repair fidelity studies across genetic backgrounds.
- Provides predictive de-risking for genomic instability mechanisms relevant to oncology and genome editing safety.
Pipeline & Workflow Integration
This NGS-based mutation mapping method integrates into the discovery-to-preclinical continuum, bridging early mechanistic studies and translational biomarker development.
- Discovery Biology: Empowers hypothesis testing on DNA repair pathway function and mutagenic risk at specific loci.
- Screening: Delivers quantitative, reproducible mutation data for compound or genetic perturbation evaluation.
- Analytics: Provides high-resolution mutation spectra and statistical comparisons between experimental conditions.
- Translational Research: Enables assessment of repair fidelity in disease-relevant or genetically engineered models.
- Enterprise Reuse: Adaptable to any transfectable cell line and genomic locus, supporting broad R&D deployment.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in DNA repair target validation and mechanistic studies.
- Operational Value: Reduces sequencing and computational costs while maintaining robust, reproducible outputs.
- Strategic Value: Informs go/no-go decisions by clarifying repair pathway liabilities and mutagenic outcomes.
- Portfolio Impact: Supports risk-adjusted prioritization of targets and interventions affecting genome stability.
Implementation Considerations
- Requires expertise in cell culture, transfection, and NGS library preparation.
- Needs access to immunoblot and immunofluorescence platforms for transfection and DSB induction validation.
- Demands standardized protocols for cross-team reproducibility and data comparability.
- Adaptable to various cell lines and loci, provided transfection and sgRNA design are feasible.
- Dependent on accurate quantification of transfection efficiency and DSB induction for data interpretation.
Biopharma FAQs
Why does null hypothesis testing matter for Cas9-induced DSB repair studies?
Null hypothesis testing enables objective assessment of whether observed mutation frequencies or types differ significantly between experimental groups, supporting robust target validation and mechanistic de-risking in DNA repair research.
How does independent variable isolation fit the Cas9/sgRNA mutation mapping workflow?
By controlling variables such as cell line, transfection efficiency, and exposure to repair modulators, the workflow isolates the impact of specific factors on DSB repair outcomes, enhancing interpretability and predictive value for discovery teams.
What do quantitative dependent variable measurements enable in this NGS protocol?
Quantitative mutation counts and spectra allow direct comparison of repair fidelity and mutagenic potential across conditions, enabling data-driven decisions on target prioritization and risk assessment in early R&D.
Why are replication requirements critical for cross-functional collaboration in DSB repair analysis?
Replication ensures that mutation detection and repair outcome measurements are reproducible across experiments and teams, supporting standardized data interpretation and enterprise-wide confidence in findings.
What statistical analysis capabilities are required before implementing this targeted NGS workflow?
Teams need the ability to perform mutation frequency comparisons, assess statistical significance, and control for confounders such as transfection efficiency to ensure reliable, actionable insights from the mutation mapping data.
